Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3-Reference-Cited by-同舟云学术

Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3

Published:2018-06-12 Issue:1 Volume:30 Page:19-26
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Kemény Lajos¹²,Berggren Lovisa³,Dossenbach Martin³,Dutronc Yves⁴,Paul Carle⁵

Affiliation:

1. MTA SZTE Dermatological Research Group, University of Szeged, Szeged, Hungary;

2. Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary;

3. Lilly Deutschland GmbH, Bad Homburg, Germany;

4. Eli Lilly and Company, Indianapolis, IN, USA;

5. Department of Dermatology, Paul Sabatier University and CHU Toulouse, Toulouse, France

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2018.1473551

Reference22 articles.

1. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

2. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

3. The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis

4. A quantitative definition of severe psoriasis for use in clinical trials

5. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials;Frontiers in Medicine;2024-03-06

2. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium;Immunotherapy;2023-10

3. Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics;European Journal of Dermatology;2023-10

4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12

5. A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries;British Journal of Dermatology;2023-03-27